Six-Month Standing Order – Quidel Ortho Reagents

The National Institutes of Health, on behalf of the Department of Transfusion Medicine, is procuring a six-month standing order of Quidel Ortho reagents and related diagnostic supplies through a sole source acquisition. This pre-solicitation notice indicates the agency's intent to award a firm-fixed-price purchase order to QuidelOrtho Sales Company, LLC without issuing a formal solicitation or requesting competitive quotations. The requirement encompasses specialized in vitro diagnostic reagents, including Anti-IgG gel cards, MTS A/B/D Mono and Reverse gel cards, Anti-IgG C3d gel cards, controls, diluents, and related testing supplies. The justification for sole source procurement centers on compatibility with the department's existing Vision analyzer and the absence of authorized alternative distributors, with the agency noting that switching to alternate products would necessitate validation and cause delays in patient care. The deadline for submitting capability statements to shasheshe.goolsby@nih.gov is March 25, 2026 at 9:30 AM EST.

This acquisition involves no set-aside designations and is being conducted under FAR Part 13 simplified acquisition procedures for purchases not exceeding the simplified acquisition threshold, which exempts the procurement from standard competition requirements. QuidelOrtho Sales Company, LLC is the identified sole source contractor at 9975 Summers Ridge Road, San Diego, California 92121-2997. The period of performance extends from April 1, 2026 through September 30, 2026, establishing a six-month contract term. While specific dollar values are not disclosed in this pre-solicitation notice, the procurement encompasses multiple line items for diagnostic reagents and control materials essential to the department's blood transfusion operations. Interested parties should note that this notice explicitly states no request for quotation will be issued and no quotations will be requested, as the award decision has been predetermined based on sole source justifications.